/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Veracyte, Inc. Share Price Today: Live Updates & Key Insights

Veracyte, Inc. share price today is $30.93, up -4.71%. The stock opened at $31.51 against the previous close of $32.46, with an intraday high of $31.755 and low of $30.67.

Veracyte, Inc. Share Price Chart

style
pb-0

Veracyte, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Veracyte, Inc. Share Price Performance

$30.93 -0.0471(-4.71%) VCYT at 13 Mar 2026 03:43 PM Diagnostics & Research
Lowest Today 30.67
Highest Today 31.755
Today’s Open 31.51
Prev. Close 32.46
52 Week High 50.71
52 Week Low 22.61
Day’s Range: Low 30.67 High 31.755
52-Week Range: Low 22.61 High 50.71
1 day return -
1 Week return -8.56
1 month return -13.44
3 month return -28.94
6 month return -2.8
1 year return +1.87
3 year return +36.41
5 year return -42.59
10 year return -

Veracyte, Inc. Institutional Holdings

BlackRock Inc 16.43

Vanguard Group Inc 10.70

Artisan Partners Limited Partnership 7.88

FMR Inc 7.22

iShares Core S&P Small-Cap ETF 6.03

ARK Investment Management LLC 5.62

State Street Corp 5.29

Dimensional Fund Advisors, Inc. 3.52

Vanguard Total Stock Mkt Idx Inv 3.13

ARK Disruptive Innovation Full Composite 3.11

ARK Innovation ETF 2.65

Wellington Management Company LLP 2.56

First Trust NYSE Arca Biotech ETF 2.44

iShares Russell 2000 ETF 2.41

Geode Capital Management, LLC 2.38

Vanguard Small Cap Index 2.25

Vanguard Explorer Inv 2.02

ArrowMark Colorado Holdings, LLC (ArrowMark Partners) 1.97

Amova Asset Management Americas, Inc 1.87

Sumitomo Mitsui Trust Group Inc 1.87

State Street® SPDR® S&P® Biotech ETF 1.81

The Goldman Sachs Group Inc 1.69

First Trust Advisors L.P. 1.67

Artisan Mid Cap Investor 1.66

Artisan U.S. Mid-Cap Growth 1.66

Bank of America Corp 1.64

GW&K Investment Management, LLC 1.62

ARK Genomic Revolution ETF 1.36

Northern Trust Corp 1.35

ARK Genomic Revolution 1.33

JPMorgan Chase & Co 1.31

Fidelity Select Health Care 1.26

Fidelity Select Medical Tech and Devcs 1.26

Vanguard Small Cap Growth Index Inv 1.25

Iron Triangle Partners LP 1.23

FullerThaler Behavioral Small-Cap Growth 1.22

Fidelity Small Cap Growth 1.16

Charles Schwab Investment Management Inc 1.15

FullerThaler Behavioral Sm-Cp Gr R6 1.12

Bridge Builder Small/Mid Cap Growth 1.08

Veracyte, Inc. Market Status

Strong Buy: 7

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 1

Veracyte, Inc. Fundamentals

Market Cap 2579.22 M

PB Ratio 1.9889

PE Ratio 40.0741

Enterprise Value 2231.41 M

Total Assets 1406.02 M

Volume 672375

Veracyte, Inc. Company Financials

Annual Revenue FY25:517145000 517.1M, FY23:343149000 343.1M, FY22:296536000 296.5M, FY21:219514000 219.5M, FY20:117483000 117.5M

Annual Profit FY25:360045000 360.0M, FY23:232791000 232.8M, FY22:194954000 195.0M, FY21:145114000 145.1M, FY20:76028000 76.0M

Annual Net worth FY25:66353000 66.4M, FY23:-49955000 -50.0M, FY22:-36560000 -36.6M, FY21:-75563000 -75.6M, FY20:-35847000 -35.8M

Quarterly Revenue Q4/2025:140636000 140.6M, Q3/2025:131872000 131.9M, Q2/2025:130164000 130.2M, Q1/2025:114473000 114.5M, Q4/2024:118632000 118.6M

Quarterly Profit Q4/2025:104680000 104.7M, Q3/2025:91282000 91.3M, Q2/2025:89769000 89.8M, Q1/2025:79508000 79.5M, Q4/2024:78754000 78.8M

Quarterly Net worth Q4/2025:41149000 41.1M, Q3/2025:19137000 19.1M, Q2/2025:-980000 -1.0M, Q1/2025:7047000 7.0M, Q4/2024:5113000 5.1M

About Veracyte, Inc. & investment objective

Company Information Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Organisation Diagnostics & Research

Employees 755

Industry Diagnostics & Research

CEO Mr. Marc A. Stapley

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow